NeurAxis

Executive Summary

NeurAxis is a US-based medical device company pioneering non-invasive neuromodulation therapies for chronic disorders of gut-brain interaction (DGBIs). Its lead product, IB-Stim, is FDA-cleared for treating functional abdominal pain in pediatric and adolescent patients, offering a drug-free, non-surgical alternative. The company aims to expand the clinical utility of IB-Stim into additional indications, such as adult functional gastrointestinal disorders and other DGBIs, while pursuing broader market adoption through clinical evidence and reimbursement coverage. With a strong focus on addressing an underserved patient population, NeurAxis leverages its proprietary technology to improve outcomes and reduce reliance on pharmacological interventions. The company is privately held and headquartered in Carmel, Indiana, with a mission to transform the management of chronic gut-brain conditions through neuromodulation.

Upcoming Catalysts (preview)

• Q2 2026FDA clearance for expanded indication (e.g., adult functional dyspepsia)60% success
• Q3 2026Publication of pivotal clinical trial results for IBS-C or IBS-D50% success
• Q4 2026Reimbursement coverage decision by major U.S. payer40% success